Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1088624

Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer


Ban, Marija; Petrić Miše, Branka; Majić, Ana; Dražić, Ivanka; Vrdoljak, Eduard
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer // Future Oncology, 14 (2018), 6; 537-544 doi:10.2217/fon-2017-0491 (međunarodna recenzija, članak, stručni)


CROSBI ID: 1088624 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer

Autori
Ban, Marija ; Petrić Miše, Branka ; Majić, Ana ; Dražić, Ivanka ; Vrdoljak, Eduard

Izvornik
Future Oncology (1479-6694) 14 (2018), 6; 537-544

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
breast ; cancer ; heavily pretreated ; HER2- ; hormone receptor positive ; metastatic ; palbociclib

Sažetak
Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months ; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
KBC Split,
Medicinski fakultet, Split

Profili:

Avatar Url Eduard Vrdoljak (autor)

Avatar Url Branka Petrić Miše (autor)

Avatar Url Marija Ban (autor)

Citiraj ovu publikaciju

Ban, Marija; Petrić Miše, Branka; Majić, Ana; Dražić, Ivanka; Vrdoljak, Eduard
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer // Future Oncology, 14 (2018), 6; 537-544 doi:10.2217/fon-2017-0491 (međunarodna recenzija, članak, stručni)
Ban, M., Petrić Miše, B., Majić, A., Dražić, I. & Vrdoljak, E. (2018) Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer. Future Oncology, 14 (6), 537-544 doi:10.2217/fon-2017-0491.
@article{article, year = {2018}, pages = {537-544}, DOI = {10.2217/fon-2017-0491}, keywords = {breast, cancer, heavily pretreated, HER2-, hormone receptor positive, metastatic, palbociclib}, journal = {Future Oncology}, doi = {10.2217/fon-2017-0491}, volume = {14}, number = {6}, issn = {1479-6694}, title = {Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer}, keyword = {breast, cancer, heavily pretreated, HER2-, hormone receptor positive, metastatic, palbociclib} }
@article{article, year = {2018}, pages = {537-544}, DOI = {10.2217/fon-2017-0491}, keywords = {breast, cancer, heavily pretreated, HER2-, hormone receptor positive, metastatic, palbociclib}, journal = {Future Oncology}, doi = {10.2217/fon-2017-0491}, volume = {14}, number = {6}, issn = {1479-6694}, title = {Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer}, keyword = {breast, cancer, heavily pretreated, HER2-, hormone receptor positive, metastatic, palbociclib} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font